Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), F. Bonella (Essen, Germany), N. Blank (Heidelberg, Germany), E. Siegert (Berlin, Germany), J. Henes (Tübingen, Germany), M. Worm (Berlin, Germany), C. Sunderkoetter (Muenster, Germany), M. Schmalzing (Wuerzburg, Germany), A. Kreuter (Oberhausen, Germany), C. Guenther (Dresden, Germany), L. Susok (Bochum, Germany), G. Zeidler (Treuenbrietzen, Germany), I. Koetter (Hamburg, Germany), U. Mueller-Ladner (Bad Nauheim, Germany), T. Krieg (Cologne, Germany), A. Juche (Berlin, Germany), T. Schmeiser (Wuppertal, Germany), G. Riemekasten (Luebeck, Germany), E. Aberer (Graz, Austria), N. Gaebelein-Wissing (Wuppertal, Germany), J. Distler (Erlangen, Germany), M. Sárdy (Munich, Germany), C. Pfeiffer (Ulm, Germany), K. Kuhr (Cologne, Germany), H. Lorenz (Heidelberg, Germany), P. Moinzadeh (Cologne, Germany), N. Hunzelmann (Cologne, Germany). Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network. 3595

Member's Comments

No comment yet.

Related content which might interest you: The presence and impact of chronic kidney disease in COPD patients, data from the German COSYCONET cohort Source: International Congress 2017 – Extrapulmonary comorbidities in COPD Year: 2017 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Natural variability in the disease course of SSc-ILD: implications for treatment Source: Eur Respir Rev, 30 (159) 200340; 10.1183/16000617.0340-2020 Year: 2021 Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 The management of GERD in patients with advanced lung disease: drugs or surgery? Source: Annual Congress 2009 - The role of gastro-oesophageal reflux in advanced lung disease Year: 2009 Does large airway intervention for patients with malignant disease result in early clinical benefit? Source: Annual Congress 2008 - Hot and cold techniques Year: 2008 Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 The clinical impact of adherence to therapy in airways disease Source: Breathe, 17 (2) 210039; 10.1183/20734735.0039-2021 Year: 2021 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Patients with persistent asthma may have poor disease control despite normal lung function: baseline data from a pan-European real-life study Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 Cleaning agents and chronic lung disease: does the evidence support a link with COPD? Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health? Year: 2018 Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Cross-sectional study on therapeutic adherence and disease knowledge of patients affected by chronic obstructive pulmonary disease. Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 How does current knowledge on primarily hereditary risk factors for asthma and other lung diseases improve prevention, treatment and prognosis? Source: Annual Congress 2012 - Genetics and genomics in asthma and COPD: prediction and personalised medicine Year: 2012 What influences patient choice of antifibrotic treatment in IPF? Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Does the HLA-DRB1-genotype influence the course of disease in Danish sarcoidosis patients? Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Monitoring disease progression in COPD patients: one step beyond! Source: Eur Respir J 2014; 43: 665-667 Year: 2014 Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial Source: Eur Respir J 2010; 36: 65-73 Year: 2010